BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31888547)

  • 21. Radical surgery of oligometastatic pancreatic cancer.
    Hackert T; Niesen W; Hinz U; Tjaden C; Strobel O; Ulrich A; Michalski CW; Büchler MW
    Eur J Surg Oncol; 2017 Feb; 43(2):358-363. PubMed ID: 27856064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AQP1 and AQP3 Expression are Associated With Severe Symptoms and Poor-prognosis of the Pancreatic Ductal Adenocarcinoma.
    Zou W; Yang Z; Li D; Liu Z; Zou Q; Yuan Y
    Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):40-47. PubMed ID: 30531392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
    Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.
    Mackay TM; van Erning FN; van der Geest LGM; de Groot JWB; Haj Mohammad N; Lemmens VE; van Laarhoven HW; Besselink MG; Wilmink JW;
    Eur J Cancer; 2019 Jan; 106():99-105. PubMed ID: 30476732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population.
    Maehira H; Miyake T; Iida H; Tokuda A; Mori H; Yasukawa D; Mukaisho KI; Shimizu T; Tani M
    Ann Surg Oncol; 2019 Dec; 26(13):4791-4804. PubMed ID: 31583548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival benefit of local consolidative therapy for patients with single-organ metastatic pancreatic cancer: a propensity score-matched cross-sectional study based on 17 registries.
    Hu X; Hu D; Fu B; Li H; Ren G; Liu H; Song J; Kang X; Wang X; Pang H; Liu C; Zhang J; Wang Y
    Front Endocrinol (Lausanne); 2023; 14():1225979. PubMed ID: 38027134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DWI of Pancreatic Ductal Adenocarcinoma: A Pilot Study to Estimate the Correlation With Metastatic Disease Potential and Overall Survival.
    Garces-Descovich A; Morrison TC; Beker K; Jaramillo-Cardoso A; Moser AJ; Mortele KJ
    AJR Am J Roentgenol; 2019 Feb; 212(2):323-331. PubMed ID: 30667305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
    Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
    Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
    Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival.
    Nizri E; Sternbach N; Bar-David S; Ben-Yehuda A; Gerstenhaber F; Ofir T; Wolf I; Weiner G; Lahat G; Klausner J
    Ann Surg Oncol; 2018 Feb; 25(2):475-481. PubMed ID: 29124488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis.
    Tachezy M; Gebauer F; Janot M; Uhl W; Zerbi A; Montorsi M; Perinel J; Adham M; Dervenis C; Agalianos C; Malleo G; Maggino L; Stein A; Izbicki JR; Bockhorn M
    Surgery; 2016 Jul; 160(1):136-144. PubMed ID: 27048934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
    Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
    Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma.
    Satoi S; Yanagimoto H; Yamamoto T; Toyokawa H; Hirooka S; Yamaki S; Opendro SS; Inoue K; Michiura T; Ryota H; Matsui Y; Kon M
    World J Surg Oncol; 2016 Jan; 14(1):14. PubMed ID: 26791083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma.
    von Delius S; Ayvaz M; Wagenpfeil S; Eckel F; Schmid RM; Lersch C
    Thromb Haemost; 2007 Aug; 98(2):434-9. PubMed ID: 17721628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study.
    Decoster C; Gilabert M; Autret A; Turrini O; Oziel-Taieb S; Poizat F; Giovannini M; Viens P; Iovanna J; Raoul JL
    Oncotarget; 2016 Jul; 7(29):45649-45655. PubMed ID: 27286454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib.
    Lu X; Gu W; Zhang H; Zhu Y; Shi G; Ye D
    Oncotarget; 2016 May; 7(18):26879-87. PubMed ID: 27058898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy.
    de Ortiz de Choudens S; Visotcky A; Banerjee A; Aldakkak M; Tsai S; Evans DB; Christians KK; Clarke CN; George B; Shreenivas A; Kamgar M; Chakrabarti S; Dua KS; Khan AH; Madhavan S; Erickson BA; Hall WA
    Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38140796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
    Frost N; Tessmer A; Schmittel A; van Laak V; Raspe M; Ruwwe-Glösenkamp C; Brunn M; Senger C; Böhmer D; Ochsenreither S; Temmesfeld-Wollbrück B; Furth C; Schmidt B; Neudecker J; Rückert JC; Suttorp N; Witzenrath M; Grohé C
    Lung Cancer; 2018 Nov; 125():164-173. PubMed ID: 30429016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.